Abstract:Protein kinase CK2 (designated CSNK2) is a constitutively active protein kinase with a vast repertoire of putative substrates that has been implicated in several human cancers, including cancer of the breast, lung, colon, and prostate, as well as hematologic malignancies. On the basis of these observations, CSNK2 has emerged as a candidate for targeted therapy, with two CSNK2 inhibitors in ongoing clinical trials. CX-4945 is a bioavailable small-molecule ATP-competitive inhibitor targeting its active site, and CIGB-300 is a cell-permeable cyclic peptide that prevents phosphorylation of the E7 protein of HPV16 by CSNK2. In preclinical models, either of these inhibitors exhibit antitumor efficacy. Furthermore, in combinations with chemotherapeutics such as cisplatin or gemcitabine, either CX-4945 or CIGB-300 promote synergistic induction of apoptosis. While CSNK2 is a regulatory participant in many processes related to cancer, its potential to modulate caspase action may be particularly pertinent to its emergence as a therapeutic target. Because the substrate recognition motifs for CSNK2 and caspases are remarkably similar, CSNK2 can block the cleavage of many caspase substrates through the phosphorylation of sites adjacent to cleavage sites. Phosphoproteomic strategies have also revealed previously underappreciated roles for CSNK2 in the phosphorylation of several key constituents of DNA damage and DNA repair pathways. Going forward, applications of proteomic strategies to interrogate responses to CSNK2 inhibitors are expected to reveal signatures for CSNK2 inhibition and molecular insights to guide new strategies to interfere with its potential to inhibit caspase action or enhance the susceptibility of cancer cells to DNA damage. Clin Cancer Res; 22(12); 2840-7. ©2016 AACR.

CKS1B as Drug Resistance-Inducing Gene—A Potential Target to Improve Cancer Therapy

Biological functions and therapeutic potential of CKS2 in human cancer

Targeting casein kinase 1 for cancer therapy: current strategies and future perspectives

Functions and Inhibitors of CHK1 in Cancer Therapy

Targeting CDK7 in oncology: The avenue forward.

CKS1B as a potential target for prognostic assessment and intervention in pancreatic cancer and its role in abnormal proliferation and cellular phenotype through mediation of cell cycle signaling pathways

Targeting cyclin-dependent kinases in gastrointestinal cancer therapy.

Effects of Altered Expression and Activity Levels of CK1δ and Ɛ on Tumor Growth and Survival of Colorectal Cancer Patients

Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells

Regulation of cancer progression by CK2: an emerging therapeutic target

Potential Target of CDK6 Signaling Pathway for Cancer Treatment

Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.

A Pan-Cancer Analysis of Clinical Prognosis and Immune Infiltration of CKS1B in Human Tumors

Cancer-keeper Genes As Therapeutic Targets.

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target

Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects

Identification of cancer-keeping genes as therapeutic targets by finding network control hubs

Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy

PI3K/AKT Inhibitors as Sensitizing Agents for Cancer Chemotherapy

Cks1: Structure, Emerging Roles and Implications in Multiple Cancers

CDK1 Promotes Nascent DNA Synthesis and Induces Resistance of Cancer Cells to DNA-damaging Therapeutic Agents.